Article
Cell Biology
Shangang Zhao, Qian Lin, Wei Xiong, Li Li, Leon Straub, Dinghong Zhang, Rizaldy Zapata, Qingzhang Zhu, Xue-Nan Sun, Zhuzhen Zhang, Jan-Bernd Funcke, Chao Li, Shiuhwei Chen, Yi Zhu, Nisi Jiang, Guannan Li, Ziying Xu, Steven C. Wyler, May-Yun Wang, Juli Bai, Xianlin Han, Christine M. Kusminski, Ningyan Zhang, Zhiqiang An, Joel K. Elmquist, Olivia Osborn, Chen Liu, Philipp E. Scherer
Summary: Antipsychotic drugs can cause weight gain and diabetes, and hyperleptinemia plays a key role. Suppression of leptin rise can reduce the adverse effects of these drugs.
SCIENCE TRANSLATIONAL MEDICINE
(2023)
Article
Obstetrics & Gynecology
Johanna Molin, Eszter Vanky, Tone S. Lovvik, Eva Dehlin, Marie Bixo
Summary: Excessive gestational weight gain (GWG) is associated with enhanced leptin resistance and attenuated physiological increase in serum allopregnanolone levels during pregnancy. Metformin reduces the risk of excessive GWG in pregnant women with PCOS and improves leptin sensitivity.
BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY
(2022)
Article
Chemistry, Medicinal
Anna Partyka, Katarzyna Gorecka, Joanna Gdula-Argasinska, Natalia Wilczynska-Zawal, Magdalena Jastrzebska-Wiesek, Anna Wesolowska
Summary: Patients taking antipsychotic drugs have a higher likelihood of developing metabolic syndrome, characterized by abdominal obesity, elevated glucose levels, and dyslipidemia. Current treatments for the metabolic side effects of antipsychotic drugs are not satisfactory. Ligands of the serotonin 6 receptor may offer a promising supplement to antipsychotic therapy. This study examined the effects of different antipsychotic drugs alone and in combination with a selective 5-HT6 agonist or antagonist on weight gain, food intake, lipid profile, glucose level, and adipose and gastrointestinal hormones in rats.
Article
Health Care Sciences & Services
Anastasiia S. Boiko, Irina A. Mednova, Elena G. Kornetova, Anastasiia A. Goncharova, Arkadiy Semke, Nikolay A. Bokhan, Svetlana A. Ivanova
Summary: Metabolic syndrome (MetS) is a common complication of schizophrenia that is exacerbated by long-term use of antipsychotics. The study found that levels of leptin were significantly increased in MetS patients, while ghrelin levels were significantly decreased. There were fewer significant correlations between ghrelin and other hormones in MetS patients compared to those without MetS.
JOURNAL OF PERSONALIZED MEDICINE
(2022)
Review
Psychology, Multidisciplinary
Yanisa Wannasuphoprasit, Stig Ejdrup Andersen, Maria J. Arranz, Rosa Catalan, Gesche Jurgens, Sanne Maartje Kloosterboer, Henrik Berg Rasmussen, Anjali Bhat, Haritz Irizar, Dora Koller, Renato Polimanti, Baihan Wang, Eirini Zartaloudi, Isabelle Austin-Zimmerman, Elvira Bramon
Summary: The CYP2D6 genetic variation may influence weight gain in individuals taking antipsychotic medications, but further large-scale studies are needed to confirm the association.
FRONTIERS IN PSYCHOLOGY
(2022)
Article
Medicine, General & Internal
Stefanie N. Hinkle, Sunni L. Mumford, Katherine L. Grantz, Pauline Mendola, James L. Mills, Edwina H. Yeung, Anna Z. Pollack, Sonia M. Grandi, Rajeshwari Sundaram, Yan Qiao, Enrique F. Schisterman, Cuilin Zhang
Summary: Gestational weight change is associated with mortality over 50 years later, with sustained excessive or reduced weight being associated with increased risk of cardiovascular and diabetes-related deaths.
Article
Multidisciplinary Sciences
Maarten Bak, Marjan Drukker, Shauna Cortenraad, Emma Vandenberk, Sinan Guloksuz
Summary: This meta-analysis found that antipsychotics are associated with body weight gain, regardless of psychiatric diagnosis.
Article
Pharmacology & Pharmacy
Farhana Islam, Xiaoyu Men, Kazunari Yoshida, Clement C. Zai, Daniel J. Mueller
Summary: Pharmacogenetics research has shown that genetic factors influence the efficacy and tolerability of antipsychotic treatment, with the most robust findings related to associations between polymorphisms in CYP2D6 and exposure and response to specific antipsychotics. Product labels and guidelines have provided dosing recommendations based on CYP2D6 metabolizer phenotypes.
CLINICAL PHARMACOLOGY & THERAPEUTICS
(2021)
Article
Health Care Sciences & Services
Gesche Jurgens, Benjamin Skov Kaas-Hansen, Merete Nordentoft, Thomas Werge, Stig Ejdrup Andersen
Summary: This study found an association between genetically predicted CYP2D6 metabolic capacity and antipsychotic-induced weight gain. The results showed significant weight gain in both CYP2D6 poor metabolizers and ultrarapid metabolizers after taking antipsychotic drugs.
JOURNAL OF PERSONALIZED MEDICINE
(2022)
Article
Behavioral Sciences
Tatiana de Queiroz Oliveira, Adriano Jose Maia Chaves Filho, Paloma Marinho Juca, Michelle Verde Ramos Soares, Natassia Lopes Cunha, Charliene Freire Xavier Vieira, Carlos Venicio Jatai Gadelha Filho, Glautemberg de Almeida Viana, Gabriela Mariangela Farias De Oliveira, Danielle Silveira Macedo, Silvania Maria Mendes Vasconcelos
Summary: This study showed that lipoic acid (ALA) can reverse the weight and metabolic changes induced by Mirtazapine (MIRT), while maintaining its antidepressant and pro-cognitive effects. The combination of ALA with MIRT reduced weight gain, serum corticosterone levels, and SERT expression in the hippocampus. Our findings suggest that the ALA+MIRT combination may serve as a new therapeutic strategy for depression treatment with less side effects.
BEHAVIOURAL BRAIN RESEARCH
(2022)
Review
Endocrinology & Metabolism
Douglas Tremblay, Mikaela Dougherty, John Mascarenhas, Emily Jane Gallagher
Summary: Weight gain is a common side effect of ruxolitinib, and this study suggests that it may be related to changes in whole body energy expenditure.
FRONTIERS IN ENDOCRINOLOGY
(2023)
Article
Psychiatry
Yuying Qiu, Meijuan Li, Yonghui Zhang, Ying Liu, Yongping Zhao, Jing Zhang, Qiong Jia, Jie Li
Summary: Berberine could reduce weight gain in schizophrenia patients, with significant weight loss observed in the berberine group compared to placebo. The effect may be related to the regulation of leptin levels.
ASIAN JOURNAL OF PSYCHIATRY
(2022)
Article
Psychology, Developmental
Hua Chen, Ning Lyu, Wenyaw Chan, Austin De La Cruz, Chadi Calarge
Summary: This study examines the utilization and predictors of adjuvant metformin among pediatric recipients of second-generation antipsychotics. The findings suggest that the utilization of adjuvant metformin is uncommon among pediatric SGA recipients, and early introduction of the medication among nonobese children is rare.
JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY
(2023)
Review
Endocrinology & Metabolism
Helene Speyer, Casper Westergaard, Nikolai Albert, Mette Karlsen, Anne Emilie Sturup, Merete Nordentoft, Jesper Krogh
Summary: The study found that reducing dosage, discontinuing medication, or switching to a partial agonist can lead to a small but significant weight loss of around 1.5 kg. The overall weight change from pre to post intervention was a reduction of 1.13 kg.
FRONTIERS IN ENDOCRINOLOGY
(2021)
Review
Psychiatry
Laura Mead, Alice Ayres, Julie A. Blake, James G. Scott
Summary: The review found that metabolic monitoring of children and adolescents prescribed antipsychotic medication is inconsistent and insufficient, especially for biochemical parameters requiring venesection. Implementation of quality improvement activities can improve monitoring rates, but measurement of biochemical parameters still only occurs in a minority of children.
AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY
(2021)